# Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients

> **NCT02014103** · PHASE4 · COMPLETED · sponsor: **University of Cincinnati** · enrollment: 71 (actual)

## Conditions studied

- Complication of Transplant

## Interventions

- **DRUG:** Prograf
- **DRUG:** Tacrolimus, Sandoz
- **DRUG:** Tacrolimus, Reddy Laboratory
- **DRUG:** Tacrolimus, Mylan
- **DRUG:** Tacrolimus, Accord
- **DRUG:** Tacrolimus, Pancea Biotech Limited

## Key facts

- **NCT ID:** NCT02014103
- **Lead sponsor:** University of Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2024-10-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02014103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02014103, "Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02014103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*